Xie Lingchao, Yoon Bu Hyun, Park Chanhee, You Joshua Sung H
Sports Movement Artificial Robotics Technology (SMART) Institute, Department of Physical Therapy, Yonsei University, Wonju 26493, Korea.
Department of Physical Therapy, Yonsei University, Wonju 26493, Korea.
Brain Sci. 2022 Aug 10;12(8):1058. doi: 10.3390/brainsci12081058.
This study was designed to determine the best intervention time (acute, subacute, and chronic stages) for Walkbot robot-assisted gait training (RAGT) rehabilitation to improve clinical outcomes, including sensorimotor function, balance, cognition, and activities of daily living, in hemiparetic stroke patients. Thirty-six stroke survivors (acute stage group (ASG), = 11; subacute stage group (SSG), = 15; chronic stage group (CSG), = 10) consistently received Walkbot RAGT for 30 min/session, thrice a week, for 4 weeks. Six clinical outcome variables, including the Fugl-Meyer Assessment (FMA), Berg Balance Scale (BBS), Trunk Impairment Scale (TIS), Modified Barthel Index (MBI), Modified Ashworth Scale (MAS), and Mini-Mental State Examination, were examined before and after the intervention. Significant differences in the FMA, BBS, TIS, and MBI were observed between the ASG and the SSG or CSG. A significant time effect was observed for all variables, except for the MAS, in the ASG and SSG, whereas significant time effects were noted for the FMA, BBS, and TIS in the CSG. Overall, Walkbot RAGT was more favorable for acute stroke patients than for those with subacute or chronic stroke. This provides the first clinical evidence for the optimal intervention timing for RAGT in stroke.
本研究旨在确定Walkbot机器人辅助步态训练（RAGT）康复的最佳干预时间（急性期、亚急性期和慢性期），以改善偏瘫中风患者的临床结局，包括感觉运动功能、平衡、认知和日常生活活动能力。36名中风幸存者（急性期组（ASG），n = 11；亚急性期组（SSG），n = 15；慢性期组（CSG），n = 10）持续接受Walkbot RAGT，每次30分钟，每周三次，共4周。在干预前后检查了六个临床结局变量，包括Fugl-Meyer评估（FMA）、Berg平衡量表（BBS）、躯干损伤量表（TIS）、改良Barthel指数（MBI）、改良Ashworth量表（MAS）和简易精神状态检查。在ASG与SSG或CSG之间观察到FMA、BBS、TIS和MBI存在显著差异。在ASG和SSG中，除MAS外，所有变量均观察到显著的时间效应，而在CSG中，FMA、BBS和TIS观察到显著的时间效应。总体而言，Walkbot RAGT对急性中风患者比对亚急性或慢性中风患者更有利。这为中风患者RAGT的最佳干预时机提供了首个临床证据。
